CA1323834C - Controlled release dosage forms having a defined water content - Google Patents

Controlled release dosage forms having a defined water content

Info

Publication number
CA1323834C
CA1323834C CA000600949A CA600949A CA1323834C CA 1323834 C CA1323834 C CA 1323834C CA 000600949 A CA000600949 A CA 000600949A CA 600949 A CA600949 A CA 600949A CA 1323834 C CA1323834 C CA 1323834C
Authority
CA
Canada
Prior art keywords
dosage form
oral dosage
form according
weight
wax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000600949A
Other languages
English (en)
French (fr)
Inventor
Joanne Heafield
Stewart Thomas Leslie
Sandra Therese Antoinette Malkowska
Philip John Neale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of CA1323834C publication Critical patent/CA1323834C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA000600949A 1988-06-02 1989-05-29 Controlled release dosage forms having a defined water content Expired - Lifetime CA1323834C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8813064 1988-06-02
GB888813064A GB8813064D0 (en) 1988-06-02 1988-06-02 Controlled release dosage forms having defined water content

Publications (1)

Publication Number Publication Date
CA1323834C true CA1323834C (en) 1993-11-02

Family

ID=10637952

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000600949A Expired - Lifetime CA1323834C (en) 1988-06-02 1989-05-29 Controlled release dosage forms having a defined water content

Country Status (19)

Country Link
US (1) US5091189A (no)
EP (1) EP0344960B1 (no)
JP (1) JPH0816060B2 (no)
KR (1) KR0136279B1 (no)
AT (1) ATE83925T1 (no)
AU (1) AU610401B2 (no)
CA (1) CA1323834C (no)
DE (1) DE68904119T2 (no)
DK (1) DK175130B1 (no)
ES (1) ES2053989T3 (no)
FI (1) FI93695C (no)
GB (2) GB8813064D0 (no)
GR (1) GR3007088T3 (no)
IE (1) IE61998B1 (no)
IL (1) IL90462A (no)
NO (1) NO176232C (no)
NZ (1) NZ229372A (no)
PT (1) PT90722B (no)
ZA (1) ZA894201B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
SI1685839T1 (sl) 1997-12-22 2013-08-30 Euro-Celtique S.A. Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
EP1133230A4 (en) 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
NZ520554A (en) 2000-02-08 2005-08-26 Euro Celtique S Tamper-resistant oral opioid agonist formulations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
IN192180B (no) * 2001-09-28 2004-03-06 Ranbaxy Lab
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
KR20040098050A (ko) 2002-04-05 2004-11-18 유로-셀띠끄 소시에떼 아노님 옥시코돈 및 날록손을 포함하는 약제학적 제제
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
JP2006515008A (ja) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド 経口投与のためのミルナシプランの多粒子状組成物
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP2039349A1 (en) * 2004-10-19 2009-03-25 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising donepezil hydrochloride
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
RU2385712C2 (ru) * 2005-08-24 2010-04-10 Рубикон Рисёч Пвт Лтд. Рецептура с контролируемым высвобождением
US8158156B2 (en) * 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
CA2662358C (en) * 2006-09-29 2015-02-10 The Procter & Gamble Company Oral compositions containing gel networks
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
CA2730211C (en) * 2008-07-07 2016-11-08 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
EP2405915B1 (en) 2009-03-10 2018-10-24 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CN114053235B (zh) * 2020-08-07 2023-07-18 广州白云山光华制药股份有限公司 茶碱缓释片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4743247A (en) * 1984-08-13 1988-05-10 Alza Corporation Process for manufacturing dosage form
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ATE107857T1 (de) * 1986-06-10 1994-07-15 Euro Celtique Sa Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids

Also Published As

Publication number Publication date
GB2219207B (en) 1992-01-02
DE68904119T2 (de) 1993-06-09
AU3512789A (en) 1989-12-07
NO892229L (no) 1989-12-04
EP0344960A2 (en) 1989-12-06
DE68904119D1 (de) 1993-02-11
DK266889D0 (da) 1989-06-01
AU610401B2 (en) 1991-05-16
PT90722B (pt) 1994-11-30
US5091189A (en) 1992-02-25
GB2219207A (en) 1989-12-06
IE61998B1 (en) 1994-12-14
NZ229372A (en) 1991-07-26
JPH0816060B2 (ja) 1996-02-21
FI892664A (fi) 1989-12-03
FI93695C (fi) 1995-05-26
IE891744L (en) 1989-12-02
KR0136279B1 (ko) 1998-04-25
IL90462A0 (en) 1990-01-18
GB8813064D0 (en) 1988-07-06
ATE83925T1 (de) 1993-01-15
FI892664A0 (fi) 1989-06-01
IL90462A (en) 1993-01-31
NO892229D0 (no) 1989-06-01
NO176232C (no) 1995-03-01
ES2053989T3 (es) 1994-08-01
EP0344960B1 (en) 1992-12-30
ZA894201B (en) 1990-03-28
JPH0225420A (ja) 1990-01-26
GB8911629D0 (en) 1989-07-05
DK266889A (da) 1989-12-03
GR3007088T3 (no) 1993-07-30
DK175130B1 (da) 2004-06-14
KR900000077A (ko) 1990-01-30
FI93695B (fi) 1995-02-15
NO176232B (no) 1994-11-21
EP0344960A3 (en) 1990-03-07
PT90722A (pt) 1989-12-29

Similar Documents

Publication Publication Date Title
CA1323834C (en) Controlled release dosage forms having a defined water content
CA1296254C (en) Spheroids containing 3-alkylxanthine
JP3667778B2 (ja) スフェロイド製剤
CZ344199A3 (cs) Farmaceutický prostředek pro orální podávání derivátu N-piperidin-3-pyrazolkarboxamidu, jeho solí nebo solvátů a způsob jeho přípravy
EP0571973B1 (en) Slow-release sodium valproate tablets
KR0177493B1 (ko) 단사정계 결정구조를 갖고 감열, 감광 및 감습성이 있는 활성성분을 함유하는 정제의 제조방법
CN104844600A (zh) 一种他达拉非化合物、及其组合物
AU621706B2 (en) Stabilizing system for solid dosage forms
EP1965773A1 (en) Oral formulation of anhydrous olanzapine form i
CZ57793A3 (en) Hard capsules of cytarabia-ocphosphate
DK166259B (da) Oral tablet til ph-uafhaengig frigivelse
CN113081989A (zh) 别嘌醇缓释片剂
JPH07112934A (ja) ペントキシフィリンの徐放化製剤およびその製法
EP1104673A1 (en) A hydrogen carbonate-containing, desintegrating agent-free pharmaceutical composition
PT97970A (pt) Processo para a preparacao de composicoes melhoradas de acido 5-(2,5-dimetilfenoxi)-2,2-dimetilpentanoico (gemefibrozil)
JP2002226371A (ja) プラバスタチンナトリウムの錠剤
MXPA00011182A (en) Pharmaceutical preparation containing levothyroxine sodium

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20101102